Wikipedia:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Fibrinolysin: Difference between pages

<!-- Clinical data -->

| Verifiedfields = changed

| verifiedrevid = 480476518

| routes_of_administration = ointment for local application, in combination with deoxyribonuclease

<!-- Pharmacokinetic data -->

<!-- Identifiers -->

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 9004-09-5

| DrugBank_Ref = {{drugbankcite|changed|drugbank}}

| DrugBank = DB08977

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = A4028U842W

| ChEMBL_Ref = {{ebicite|changed|EBI}}

| ChEMBL = 1201505

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

<!-- Chemical data -->

'''Fibrinolysin''' is an enzyme derived from plasma of [[bovine]] origin ([[plasmin]]) or extracted from cultures of certain [[bacteria]]. It is used locally only and exclusively together with the enzyme desoxyribonuclease (extracted from bovine pancreas). Fibrinolysin and desoxyribonuclease both act as lytic enzymes. The combination is available as ointment containing 1 BU ([[Biological unit|Biological Unit]]) fibrinolysin and 666 BUs desoxyribonuclease per gram.

Fibrinolysin attacks and inactivates [[fibrin]] molecules occurring in undesirable [[exudate]]s on the surface of the human body and on human [[mucosa]], e.g., in superficial [[wounds]] and [[Burn (injury)|burns]], while desoxyribonuclease targets and destroys (human) [[DNA]]. The combination of the two enzymes has a synergistic effect on necrotic but not on living [[biological tissue|tissue]]. According to the manufacturer the ointment provides enhanced wound cleaning and accelerates the healing process.

Both enzymes are marginally resorbed into systemic circulation because of their very high molecular weight and their macromolecular structure.

The activity of both enzymes is almost completely exhausted after 24 hours. Usually, it is necessary to repeat the application (and renew the dressing) every 6 to 8 hours until healing becomes complete.

The ointment is marketed by [[Pfizer]] under the brand name Fibrolan in a variety of countries (e.g. Switzerland). It is currently not approved in the USA.

Where approved, Fibrolan has been licensed on the basis of claimed good therapeutical experience, but adequate and well controlled studies are still lacking.

In the past, combinations with the antibiotic [[chloramphenicol]] were available, but because chloramphenicol in any form of application has led to [[aplastic anemia]] and death, these were banned. Additionally, combinations with the antifibrinolytic agent [[tranexamic acid]] have been withdrawn from pharmaceutic markets.

==Indications==

Enzymatic wound cleaning to assist healing of minor burns, superficial wounds, [[ulcus cruris]], and superficial [[hematoma]].

==Contraindications and Precautions==

The ointment should not be used in patients with a known [[hypersensitivity]] to any ingredient. It should be used with caution in patients with hypersensitivity to bovine proteins in general and in pregnant women (category C), because no human data is available.

==Side-Effects==

Infrequently, local reactions such as increased pain or a stitching/burning sensation are noticed. No systemic [[anticoagulant]] activity has been seen due to the exclusively local character of treatment.

==Interactions==

Not known.

==See also==

*[[Staphylokinase|Staphylokinase (staphylococcal fibrinolysin)]]

==External links==

* Swiss scientific product information

*{{cite journal |doi=10.1016/0003-9861(83)90053-X |vauthors=Birk Y, Khalef S, Jibson MD |title=Purification and properties of protease F, a bacterial enzyme with chymotrypsin and elastase specificities |journal=Arch. Biochem. Biophys. |volume=225 |issue=2 |pages=451–7 |date=September 1983 |pmid=6226244 }}

{{Antithrombotics}}

{{Serine endopeptidases}}

{{Enzymes}}

{{Portal bar|Biology|border=no}}

[[Category:EC 3.4.21]]

[[Category:Hydrolases]]

[[Category:Antithrombotic enzymes]]